ALZpath Inks Licensing Deal With Abbott To Expand Blood-Based Alzheimer's Disease Testing

ALZpath Inc. signed a licensing agreement with Abbott Laboratories to incorporate its proprietary phosphorylated Tau 217 antibody into an in vitro diagnostic test for Alzheimer's disease. The deal supports development of a potential diagnostic product in a large healthcare market, though no financial terms or commercialization timeline were disclosed. The news is positive for both companies but is likely to have limited immediate market impact.

Analysis

ALZpath Inc. signed a licensing agreement with Abbott Laboratories to incorporate its proprietary phosphorylated Tau 217 antibody into an in vitro diagnostic test for Alzheimer's disease. The deal supports development of a potential diagnostic product in a large healthcare market, though no financial terms or commercialization timeline were disclosed. The news is positive for both companies but is likely to have limited immediate market impact.